TRAVECTA THERAPEUTICS
ravecta is an emerging biotech company utilizing its novel Blood-Brain Barrier Transport Platform to develop a proprietary pipeline of molecules that treat disorders of the central nervous system. The Travecta Platform leverages their proprietary knowledge of the MFSD2a Transport for the targeted delivery of therapeutic agents to the brain. Their platform and know-how allow us to identify and categorize small molecules for enabling their transport across the blood-brain barrier (BBB). Additional... ly, Travecta partners with pharmaceutical companies to apply their platform and assist them in overcoming the challenges associated with delivering drugs across the BBB. Travecta’s process allows partners to rapidly confirm BBB transport through feasibility studies that generate in vitro and in vivo transport data of their molecule generated with Travecta’s proprietary models.
TRAVECTA THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Market Research
Founded:
2017-01-01
Address:
Singapore, Central Region, Singapore
Country:
Singapore
Website Url:
http://www.travectatherapeutics.com
Total Employee:
1+
Status:
Active
Total Funding:
15 M USD
Technology used in webpage:
Domain Not Resolving YouTube DoubleClick.Net DNS.COM
Similar Organizations
Circumvent
Circumvent is a biotech company
Enable Biosciences
Enable Biosciences is a biotech company.
Eureka Therapeutics
Eureka Therapeutics is a biotechnology company focusing on immunotherapies for the treatment of cancer.
Group K Diagnostics
We put patient health 1st by revolutionizing rapid blood testing with a hand-held chemistry and ID analyzer for everyone, all in one.
Iota Biosciences
Iota Biosciences is a Biotech Company.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
KBP Biosciences
A multinational clinical stage biotechnology company.
Saol Therapeutics
Saol Therapeutics is a biotech pharmaceutical company.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Current Employees Featured
Founder
Investors List
TKS1
TKS1 investment in Series A - Travecta Therapeutics
Official Site Inspections
http://www.travectatherapeutics.com
- Host name: 104.21.91.232
- IP address: 104.21.91.232
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Travecta Therapeutics"
Travecta Therapeutics - Crunchbase Company Profile
Travecta is a biotech company thatravecta is an emerging biotech company utilizing its novel Blood-Brain Barrier Transport Platform to develop a …See details»
Travecta Therapeutics - SPRIM Global Investments
Travecta Therapeutics is developing a broad portfolio of product candidates engineered to cross the blood-brain-barrier.See details»
Travecta Therapeutics Announces Broad Expansion of its Executive ...
Oct 27, 2021 Travecta Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain-barrier and blood-retinal …See details»
Travecta Therapeutics Company Profile - Craft
Travecta Therapeutics is a biotechnology company. It develops a platform to identify, simplify, and categorize small molecules for facilitating their transport across the blood-brain barrier, …See details»
Travecta Therapeutics - VentureRadar
Travecta Therapeutics is an emerging biotech company developing a platform that leverages proprietary knowledge of the MFSD2a Transport for the targeted delivery of therapeutic agents …See details»
Travecta Therapeutics Announces it has Closed its
Jun 11, 2020 Travecta Therapeutics, announces today it has raised an additional $12 million in financing, closing its Series A round at a total of $27 million.See details»
www.travectatherapeutics.com
Www.travectatherapeutics.comSee details»
Travecta Therapeutics 2025 Company Profile: …
Information on valuation, funding, cap tables, investors, and executives for Travecta Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Duke-NUS commercialises discovery to deliver therapeutics across …
Travecta Therapeutics was born from these findings and founded by Professor Silver, Dr Michael Schleifer and Mr Laurent Benissan from Sprim, a leading global health research and …See details»
Research programme: brain cancer therapies - Travecta Therapeutics
Travecta Therapeutics is developing small molecule therapeutics for the treatment of several types of brain tumors. The company is using its mVECTATM platformSee details»
Travecta Therapuetics - Crunchbase Company Profile & Funding
A bio-tech company with a proprietary solution to the blood-brain barrier.See details»
Travecta Therapeutics Announces Broad Expansion of its
Oct 27, 2021 Travecta Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain-barrier and blood-retinal …See details»
PRESS RELEASE - Print
Travecta Therapeutics was founded by experienced scientific leaders from Duke-NUS and backed by TKS1, a healthcare and life science-focused venture capital fund formed by the partnership …See details»
Travecta Therapeutics - VentureRadar
"Travecta Therapeutics is an emerging biotech company developing a platform that leverages proprietary knowledge of the MFSD2a Transport for the targeted delivery of therapeutic agents …See details»
Tackling the Blood-Brain Barrier: Duke-NUS Discovery Leads to
Mar 22, 2018 Tackling the Blood-Brain Barrier: Duke-NUS Discovery Leads to Startup Travecta By David Ho Staff Writer, BioWorld (Original article published in BioWorld) HONG KONG – …See details»
Travecta Therapeutics Announces Broad Expansion of its ... - Nasdaq
SINGAPORE and PRINCETON, N.J., Oct. 27, 2021/ PRNewswire/-- Travecta Therapeutics, Pte Ltd., a preclinical stage biopharmaceutical company pioneering a portfolio of product …See details»
Travecta Therapeutics Secures $15 Million in Financing
May 12, 2020 Travecta Therapeutics secures $15M in Series A funding led by TKS1 for developing product candidates to cross the blood-brain-barrier.See details»
Travecta Therapeutics Announces it has Closed its Oversubscribed …
Jun 11, 2020 NEW YORK and SINGAPORE – June 11, 2020 – Travecta Therapeutics, a biopharmaceutical company pioneering a portfolio of product candidates engineered to cross …See details»
Travecta Therapeutics Secures $15 Million in Financing - SPRIM
May 12, 2020 Travecta Therapeutics, a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain-barrier, announces today it has …See details»
Duke-NUS Solution to Blood-Brain Barrier Leads to Travecta
Nov 15, 2018 HONG KONG – Travecta Therapeutics Pte Ltd. is the latest startup to join Singapore’s biotech block. The newly formed drug discovery company is based on intellectual …See details»